Q1 Earnings Forecast for PROF Issued By Raymond James

Profound Medical Corp. (NASDAQ:PROF - Free Report) - Raymond James issued their Q1 2026 EPS estimates for Profound Medical in a report issued on Tuesday, February 18th. Raymond James analyst M. Freeman anticipates that the company will post earnings per share of ($0.24) for the quarter. Raymond James has a "Strong-Buy" rating on the stock. The consensus estimate for Profound Medical's current full-year earnings is ($1.12) per share. Raymond James also issued estimates for Profound Medical's Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.19) EPS and Q4 2026 earnings at ($0.14) EPS.

Profound Medical Trading Up 0.5 %

Shares of PROF stock traded up $0.04 on Wednesday, reaching $7.48. 110,588 shares of the stock were exchanged, compared to its average volume of 85,098. The company has a quick ratio of 5.16, a current ratio of 6.12 and a debt-to-equity ratio of 0.11. The stock has a market cap of $224.70 million, a P/E ratio of -5.58 and a beta of 0.88. The firm has a 50 day moving average of $7.01 and a two-hundred day moving average of $7.76. Profound Medical has a 1-year low of $5.63 and a 1-year high of $11.42.

Institutional Investors Weigh In On Profound Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in PROF. Raymond James Trust N.A. grew its holdings in shares of Profound Medical by 14.3% during the 3rd quarter. Raymond James Trust N.A. now owns 12,000 shares of the company's stock worth $96,000 after purchasing an additional 1,500 shares during the period. MTM Investment Management LLC lifted its position in Profound Medical by 10.4% during the fourth quarter. MTM Investment Management LLC now owns 18,575 shares of the company's stock valued at $139,000 after buying an additional 1,750 shares in the last quarter. Royce & Associates LP grew its stake in Profound Medical by 0.6% during the third quarter. Royce & Associates LP now owns 569,298 shares of the company's stock worth $4,529,000 after buying an additional 3,500 shares during the period. National Bank of Canada FI increased its position in shares of Profound Medical by 3.8% in the fourth quarter. National Bank of Canada FI now owns 126,508 shares of the company's stock worth $951,000 after acquiring an additional 4,671 shares in the last quarter. Finally, Letko Brosseau & Associates Inc. raised its stake in shares of Profound Medical by 1.0% in the 4th quarter. Letko Brosseau & Associates Inc. now owns 1,211,150 shares of the company's stock valued at $8,689,000 after acquiring an additional 12,375 shares during the period. 47.86% of the stock is currently owned by institutional investors and hedge funds.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.